Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03444454
Other study ID # FdG_VRRS_MS_01
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date February 26, 2018
Est. completion date June 30, 2024

Study information

Verified date May 2024
Source Fondazione Don Carlo Gnocchi Onlus
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The main aim of the study is to evaluate the efficacy of the Virtual Reality Rehabilitation System (VRRS, Khymeia) compared to usual care treatment for patients with MS at home. The effects of the intervention on outcome variables will be assessed using a randomized controlled trial design with a comparison group receiving usual care training. The investigators will assess the effect of VRRS system on the quality of life, motor, and cognitive abilities. (Phase I) In the second phase of the present study we aim to evaluate the effects induced by the treatment of active (anodal) transcranial Direct Current Stimulation (tDCS) applied to the left dorsolateral prefrontal cortex (lDLPFC) combined with VRRS compared to placebo tDCS stimulation combined with VRRS. The effects of the intervention patient-relevant outcomes will be assessed using a randomized controlled trial design with four groups. The investigators will assess the effect of VRRS system on patient-relevant outcomes motor, cognitive and participation. (Phase II)


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 136
Est. completion date June 30, 2024
Est. primary completion date December 31, 2018
Accepts healthy volunteers No
Gender All
Age group 25 Years to 70 Years
Eligibility Inclusion Criteria: - Confirmed diagnosis of Multiple Sclerosis (RR and SP) based on McDonald criteria - Education = 8 ages - Italian mother language - Right-handedness - Use of corticosteroids for three months prior to the study, having and no acute exacerbations of symptoms within three months of the study. Exclusion Criteria: - Existence of visual acuity and acoustic perception problems, to prevent performance of VRRS activities - Relapses next to the time of enrolment (3 months) - EDSS > 6.5.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
VRRS Khymeia
Participants will receive an individualized exercise program set up by the therapist. The intervention applied to the experimental group will consist of 30 sessions of Khymeia VRRS training distributed in five sessions for week, each lasting 45 minutes. Each session is constructed by alternating physical with cognitive activities. The sessions will initially be tailored to the patient's baseline characteristics. Remotely, the therapist will then adjust the participant's exercise program as appropriate, by changing exercises, level of difficulty or number of repetitions.
Usual care program
The usual care group will have written, home-based exercise program, provided to them at an initial face-to-face assessment.
VRRS Khymeia plus active tDCS
Participants will receive 5 sessions each lasting 45 minutes of an individualized home-based VRRS training combined with active (anodal) tDCS applied to the left dorsolateral prefrontal cortex over 1 week, followed by 5 weeks of home-based VRRS training. The sessions of VRRS will initially be tailored to the patient's baseline characteristics. Remotely, the therapist will then adjust the participant's exercise program as appropriate, by changing exercises, level of difficulty or number of repetitions.
VRRS Khymeia plus placebo tDCS
Participants will receive 5 sessions each lasting 45 minutes of an individualized home-based VRRS training combined with active (anodal) tDCS applied to the left dorsolateral prefrontal cortex over 1 week, followed by 5 weeks of home-based VRRS training. The sessions of VRRS will initially be tailored to the patient's baseline characteristics. Remotely, the therapist will then adjust the participant's exercise program as appropriate, by changing exercises, level of difficulty or number of repetitions.

Locations

Country Name City State
Italy Irccs Fondazione Don Carlo Gnocchi Milano MI

Sponsors (6)

Lead Sponsor Collaborator
Fondazione Don Carlo Gnocchi Onlus IRCCS Centro Neurolesi Bonino-Pulejo, Messina (IT), IRCCS Fondazione Istituto Neurologico Casimiro Mondino, Pavia (IT), IRCCS San Camillo, Venezia, Italy, IRCCS San Raffaele Roma, Istituti Clinici Scientifici Maugeri SpA

Country where clinical trial is conducted

Italy, 

References & Publications (1)

Di Tella S, Pagliari C, Blasi V, Mendozzi L, Rovaris M, Baglio F. Integrated telerehabilitation approach in multiple sclerosis: A systematic review and meta-analysis. J Telemed Telecare. 2020 Aug-Sep;26(7-8):385-399. doi: 10.1177/1357633X19850381. Epub 2019 May 27. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Change in measure of quality of life Quality of life will be measured by 54-item Multiple Sclerosis Quality of Life (MSQOL-54) questionnaire
There is no single overall score for the MSQOL-54. Two summary scores - physical health and mental health - can be derived from a weighted combination of scale scores. In addition, there are 12 subscales: physical function, role limitations-physical, role limitations-emotional, pain, emotional well-being, energy, health perceptions, social function, cognitive function, health distress, overall quality of life, and sexual function. There are also two single-item measures: satisfaction with sexual function and change in health.
Administration forms and scoring instructions can be downloaded (https://www.nationalmssociety.org/NationalMSSociety/media/MSNationalFiles/Brochures/MSQOL54_995.pdf ).
Higher values represent a better outcome
Baseline up to 6 weeks and 6 months
Secondary Change in balance Mini-Balance Evalutation System (mini-BES) Test Baseline up to 6 weeks and 6 months
Secondary Change in gait 12-item Multiple Sclerosis Walking Scale Baseline up to 6 weeks and 6 months
Secondary Change gross manual dexterity Box and Block Test Baseline up to 6 weeks and 6 months
Secondary Change in global cognitive status Montreal Cognitive Assessment (MoCA) test Baseline up to 6 weeks and 6 months
Secondary Change cognitive status Symbol Digit Modalities Test (Form Brief Repeatable Battery of Neuropsychological Tests ) Baseline up to 6 weeks and 6 months
Secondary Change in fatigue Fatigue Severity Scale
A questionnaire with 9 items (questions)
Grading of each FSS item ranges from 1 to 7, where 1 indicates strong disagreement and 7 strong agreement, and the final score represents the mean value of the 9 items
Higher values represent a worse outcome
Baseline up to 6 weeks and 6 months
Secondary Change in Emotional Traits The Regulatory Emotional Self-Efficacy (RESE) scale
The RESE scale assesses self-efficacy in expressing positive emotions and self-efficacy in managing negative emotions.
With this scale, participants rate (ranging from 1 [not well at all] to 5 [very well]) their capability to manage their emotional life. RESE scale consists of 12 items and are calculated 3 scores: 1) self-efficacy in expressing positive emotions (POS) score; 2)self-efficacy in managing negative emotions (NEG) score; 3)self-efficacy in managing despondency/distress (DES) score
Higher values within each score represent a better outcome
Baseline up to 6 weeks and 6 months
Secondary Change in Behavioral (depression) Beck Depression Inventory Baseline up to 6 weeks and 6 months
Secondary Change in Behavioral (anxiety) State-trait anxiety inventory Baseline up to 6 weeks and 6 months
See also
  Status Clinical Trial Phase
Completed NCT05528666 - Risk Perception in Multiple Sclerosis
Completed NCT03608527 - Adaptive Plasticity Following Rehabilitation in Multiple Sclerosis N/A
Recruiting NCT05532943 - Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis Phase 1/Phase 2
Completed NCT02486640 - Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon
Completed NCT01324232 - Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis Phase 2
Completed NCT04546698 - 5-HT7 Receptor Implication in Inflammatory Mechanisms in Multiple Sclerosis
Active, not recruiting NCT04380220 - Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis
Completed NCT02835677 - Integrating Caregiver Support Into MS Care N/A
Completed NCT03686826 - Feasibility and Reliability of Multimodal Evoked Potentials
Recruiting NCT05964829 - Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis N/A
Withdrawn NCT06021561 - Orofacial Pain in Multiple Sclerosis
Completed NCT03653585 - Cortical Lesions in Patients With Multiple Sclerosis
Recruiting NCT04798651 - Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis N/A
Active, not recruiting NCT05054140 - Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis Phase 2
Completed NCT05447143 - Effect of Home Exercise Program on Various Parameters in Patients With Multiple Sclerosis N/A
Recruiting NCT06195644 - Effect of Galvanic Vestibular Stimulation on Cortical Excitability and Hand Dexterity in Multiple Sclerosis Patients Phase 1
Completed NCT04147052 - iSLEEPms: An Internet-Delivered Intervention for Sleep Disturbance in Multiple Sclerosis N/A
Completed NCT03591809 - Combined Exercise Training in Patients With Multiple Sclerosis N/A
Completed NCT03594357 - Cognitive Functions in Patients With Multiple Sclerosis
Completed NCT02845635 - MS Mosaic: A Longitudinal Research Study on Multiple Sclerosis